Ainos(US:AIMD)2026-03-30 21:30Revenue and Profitability - Revenues for the year ended December 31, 2025, were $124,157, a 499% increase from $20,729 in 2024, primarily driven by AI Nose related programs [226] - Gross profit for 2025 was $102,911, compared to a gross loss of $(31,866) in 2024, reflecting the positive impact of the product mix change [230] - The operating loss for 2025 was $13,990,408, a slight increase from $13,841,204 in 2024, as the company continued to invest in growth strategies [236] - Net loss for 2025 was $14,771,012, a 1% decrease from $14,863,161 in 2024, due to reduced co-research and D&O insurance expenses [238] - The Company generated a net loss of $14,771,012 for the year ended December 31, 2025 [263] Costs and Expenses - The cost of revenues decreased to $21,246 in 2025 from $52,595 in 2024, attributed to a change in product mix [228] - Research and development (R&D) expenses were $7,749,772 in 2025, a decrease of 8% from $8,413,923 in 2024, due to reduced staffing expenditures [232] - Selling, general and administrative (SG&A) expenses increased by 18% to $6,343,547 in 2025 from $5,395,415 in 2024, driven by higher staffing and public relations costs [234] Cash Flow and Financing - As of December 31, 2025, the company had cash and cash equivalents of $417,353, down from $3,892,919 in 2024 [239] - Net cash used in operating activities decreased by 21% to $4,614,697 in 2025 from $5,808,267 in 2024, reflecting improved cash inflow from operating assets [240] - Cash received from financing activities decreased by $7,017,285, from $8,025,746 in 2024 to $1,008,461 in 2025 [243] - The Company repaid $1,000,000 to retire the Lee Note transaction in April 2025 and received $2,008,721 in proceeds from ATM transactions in 2025 [247] - The Company anticipates funding operations over the next twelve months through cash reserves, business revenues, and potential debt financing [248] - The Company entered into an At The Market Offering Agreement on May 31, 2024, with an aggregate offering price of $1,840,350 [249] - The Company sold an aggregate of 734,214 shares under the ATM facility, receiving $2,008,721 in net proceeds after deducting commissions and expenses [258] Future Outlook and Strategic Plans - The Company secured an initial commercial order of approximately $2.1 million for 1,400 AI Nose systems in semiconductor manufacturing, marking a significant step in commercialization [211] - The Company expects to allocate liquidity primarily toward advancing the AI Nose platform and supporting industrial deployments [260] - The Company may require significant cash to fund working capital and capital expenditures as it grows its commercial infrastructure [261] Asset Management - As of December 31, 2025, the Company had cash and cash equivalents of $417,353 and an accumulated deficit of $67,520,328 [262] - The Company performed an impairment testing for intangible assets related to VOC POCT products, concluding no impairment loss was recorded [270]